Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has reported that three of its partners have filed applications for Phase I clinical trials with HuCAL antibodies.
Subscribe to our email newsletter
In each case, the filing of the application will initiate an undisclosed milestone payment to MorphoSys.
The therapeutic antibodies are being developed in the therapeutic areas of cancer and inflammatory diseases.
According to MorphoSys, the announcement brings the total number of HuCAL antibodies that have entered clinical development in 2010 to six.
Apart from the three programmes announced, MorphoSys has two programmes from the alliance with Novartis and one from Centocor Ortho Biotech.
MorphoSys chief scientific officer Marlies Sproll said milestone payments from these programs are an important source of revenue for MorphoSys.
"Even more importantly, we are building substantial long-term value for the company as programs advance into and through clinical development," Sproll said.